ERBB2 and neoplasm: Clinically, molecular biomarkers—including KRAS/NRAS/BRAF mutations, HER2 amplification, PIK3CA mutations, MSI/MMR status, and the tumor microenvironment—play an important role in therapeutic decision-making [20].